Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$1.12B |
| 2 |
ExxonMobil
XOM
|
+$884M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$856M |
| 4 |
American International
AIG
|
+$594M |
| 5 |
Crown Castle
CCI
|
+$542M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.44B |
| 2 |
Gilead Sciences
GILD
|
+$1.23B |
| 3 |
DuPont de Nemours
DD
|
+$982M |
| 4 |
General Motors
GM
|
+$683M |
| 5 |
FRX
FOREST LABORATORIES INC
FRX
|
+$664M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.83% |
| 2 | Technology | 12.2% |
| 3 | Industrials | 11.56% |
| 4 | Communication Services | 11.27% |
| 5 | Consumer Discretionary | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Humana
HUM
$46.7B
| $985M | 0.36% |
9,540,959
+1,335,459
| +16% | +$131M |
|
77
CVS Health
CVS
$121B
| $962M | 0.36% |
13,446,652
-4,527,222
| -25% | -$291M |
|
78
Capital One
COF
$136B
| $960M | 0.36% |
12,530,000
| – | – |
|
79
Mondelez International
MDLZ
$79.4B
| $958M | 0.35% |
27,130,400
| – | – |
|
80
Boston Scientific
BSX
$74.5B
| $951M | 0.35% |
79,154,326
| – | – |
|
|
ENDP
81
DELISTED
Endo International plc
ENDP
| $949M | 0.35% |
14,073,200
+4,767,400
| +51% | +$272M |
|
82
Ryanair
RYAAY
$30.8B
| $938M | 0.35% |
48,702,030
+5,868,062
| +14% | +$115M |
|
|
GMCR
83
DELISTED
KEURIG GREEN MTN INC
GMCR
| $932M | 0.35% |
12,330,351
+1,790,694
| +17% | +$122M |
|
84
T-Mobile US
TMUS
$190B
| $905M | 0.34% |
26,907,788
+19,532,038
| +265% | +$535M |
|
85
Edwards Lifesciences
EW
$53.6B
| $903M | 0.33% |
82,431,600
-88,200
| -0.1% | -$994K |
|
86
Progressive
PGR
$121B
| $875M | 0.32% |
32,091,990
+7,513,990
| +31% | +$203M |
|
87
Zimmer Biomet
ZBH
$18.7B
| $865M | 0.32% |
9,556,031
+206,000
| +2% | +$17.8M |
|
88
KLA
KLAC
$272B
| $856M | 0.32% |
132,735,500
-6,876,490
| -5% | -$43.4M |
|
89
NRG Energy
NRG
$25.4B
| $851M | 0.32% |
29,640,828
+15,310,274
| +107% | +$428M |
|
90
United Airlines
UAL
$40.6B
| $845M | 0.31% |
22,342,500
+41,031
| +0.2% | +$1.44M |
|
|
RDS.A
91
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $844M | 0.31% |
12,683,098
-1,070,629
| -8% | -$67.2M |
|
92
Costco
COST
$421B
| $837M | 0.31% |
7,030,000
+675,000
| +11% | +$80.7M |
|
93
Danaher
DHR
$145B
| $816M | 0.3% |
15,718,972
+5,460
| +0% | +$268K |
|
94
TechnipFMC
FTI
$29.5B
| $805M | 0.3% |
20,716,147
| – | – |
|
95
Emerson Electric
EMR
$91.4B
| $802M | 0.3% |
11,425,980
-1,199,020
| -9% | -$80.1M |
|
|
LO
96
DELISTED
LORILLARD INC COM STK
LO
| $786M | 0.29% |
15,506,069
-12,110,655
| -44% | -$603M |
|
97
Darden Restaurants
DRI
$25.9B
| $784M | 0.29% |
16,130,999
-1,724,127
| -10% | -$79.8M |
|
98
Mattel
MAT
$4.19B
| $772M | 0.29% |
16,230,750
+188,053
| +1% | +$8.38M |
|
|
RAI
99
DELISTED
Reynolds American Inc
RAI
| $767M | 0.28% |
30,696,664
-3,966,000
| -11% | -$100M |
|
100
Healthpeak Properties
DOC
$14.2B
| $755M | 0.28% |
22,831,588
+2,748,843
| +14% | +$98M |
|
Similar funds
Capital Research Global Investors's Q4 2013 Portfolio in Review
As of Q4 2013, Capital Research Global Investors held 473 positions worth $270B, up 6.6% from $253B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Capital Research Global Investors withdrew a net $8.14B in Q4 2013, closing 44 positions and reducing 142 holdings. Its most notable exit was FOREST LABORATORIES INC, an estimated $664M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Technology and Industrials.
Against the trend, Capital Research Global Investors opened a new position in American International worth $608M.
- Capital Research Global Investors's largest Q4 2013 buy was American International: 11,917,900 shares worth $608M.
- Capital Research Global Investors added most to Amgen in Q4 2013, an estimated $1.12B increase.
- Capital Research Global Investors's biggest Q4 2013 reduction was Microsoft, cutting an estimated $2.44B.
- Capital Research Global Investors fully exited FOREST LABORATORIES INC in Q4 2013, selling an estimated $664M.
- Capital Research Global Investors's ten largest holdings make up 25% of its $270B portfolio in Q4 2013.
- Capital Research Global Investors opened 27 new positions and closed 44 in Q4 2013.
- Capital Research Global Investors's portfolio value rose 6.6% quarter-over-quarter to $270B.
Based on Capital Research Global Investors's 13F filing for Q4 2013, filed 14 Feb 2014.